

year, plans for the coming year, a budget request for the next grant year, with complete justification, and appropriate signatures, and be submitted using Form OPHS-1. A Financial Status Report (FSR) SF-269 is due 90 days after the close of each 12-month budget period. A copy of the form will be sent with the Notice of Grant Award.

VII. Agency Contact(s)

For Application Kits, submission of applications, and information on budget and business aspects of the application, please contact: WilDon Solutions, Office of Grants Management Operations Center, 1515 Wilson Boulevard, Third Floor Suite 310, Arlington, VA 22209 at 1-888-203-6161, e-mail OPHSgrantinfo@teamwildon.com, or fax 703-351-1138. Also contact Wildon Solutions with questions regarding programmatic information and/or requests for technical assistance in the preparation of the grant application.

VIII. Other Information

Not applicable.

Dated: April 13, 2007.

Wanda K. Jones,

Deputy Assistant Secretary for Health (Women's Health), Office of Public Health and Science.

[FR Doc. E7-7371 Filed 4-17-07; 8:45 am]

BILLING CODE 4150-33-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the Advisory Committee on Blood Safety and Availability

AGENCY: Department of Health and Human Services, Office of the Secretary.

ACTION: Notice.

SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood Safety and Availability (ACBSA) will hold a meeting. The meeting will be open to the public on both Thursday, May 10 and Friday, May 11, 2007.

DATES: The meeting will take place Thursday, May 10, 2007 and Friday, May 11, 2007 from 9 a.m. to 5 p.m.

ADDRESSES: Georgetown University Conference Center, 3800 Reservoir Road, NW., Washington, DC 20057.

FOR FURTHER INFORMATION CONTACT: Jerry A. Holmberg, PhD, Executive Secretary, Advisory Committee on Blood Safety and Availability, Office of Public Health and Science, Department of Health and Human Services, 1101 Wootton Parkway, Room 250, Rockville, MD

20852, (240) 453-8803, FAX (240) 453-8456, e-mail ACBSA@hhs.gov.

SUPPLEMENTARY INFORMATION: The ACBSA will receive updates on previous recommendations to include variant Creutzfeldt Jacob Disease (vCJD), Chagas, Transfusion Related Acute Lung Injury (TRALI) and West Nile Virus.

Since the last meeting, the Committee's Charter was modified and approved by Secretary Leavitt in October 2006 to include broad public health, ethical and legal issues related to transfusion and transplantation safety. In order to understand these areas of commonality, the main topic of this meeting will center on presentations and discussion of common concerns in transfusion and transplantation safety.

The new charter permits the expansion of the Committee ex-officio members to include agencies other than those currently having a permanent ex-officio seat. Representation from the Division of Organ Transplantation within the Health Resources and Services Administration (HRSA) and the Office of Cellular, Tissue, and Gene Therapy within the Food and Drug Administration (FDA) will be added as Committee ex-officio members.

Public comment will be solicited on Thursday, May 10, at noon and Friday, May 11, before noon. Comments will be limited to five minutes per speaker. Anyone planning to comment is encouraged to contact the Executive Secretary at his/her earliest convenience. Those who wish to have printed material distributed to Advisory Committee members should submit thirty (30) copies to the Executive Secretary prior to close of business May 7, 2007. Likewise, those who wish to utilize electronic data projection to the Committee must submit their materials to the Executive Secretary prior to close of business May 7, 2007.

Dated: April 13, 2007.

Jerry A. Holmberg,

Executive Secretary, Advisory Committee on Blood Safety and Availability.

[FR Doc. E7-7340 Filed 4-17-07; 8:45 am]

BILLING CODE 4150-41-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Adopting and Demonstrating the Adaptation of Prevention Techniques for Persons at Highest Risk of Acquiring or Transmitting Human Immunodeficiency Virus (ADAPT2), Funding Opportunity Announcement (FOA) Number PS07-004

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces a meeting of the aforementioned Special Emphasis Panel.

Time and Date:

8:30 a.m.–9 a.m., May 18, 2007 (Open).

9 a.m.–4 p.m., May 18, 2007 (Closed).

Place: Sheraton Midtown Atlanta Hotel at Colony Square, 188 14th Street, Atlanta, GA 30361.

Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of a research application in response to FOA PS07-004, "Adopting and Demonstrating the Adaptation of Prevention Techniques for Persons at Highest Risk of Acquiring or Transmitting Human Immunodeficiency Virus (ADAPT2)."

Contact Person For More Information: J. Felix Rogers, M.P.H., PhD, Scientific Review Administrator, Extramural Research Program Office, Centers for Disease Control and Prevention, 1600 Clifton Road, NE., MS E05, Atlanta, GA 30333, telephone 404.639.6101.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.